Clinical Trial Update: Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating low-dose buprenorphine as a modulator of social motivation in schizophrenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• buprenorphine (buprenorphine)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Schizophrenia | Phase 2 | Status: RECRUITING